Ghost Tree Capital’s Atara Biotherapeutics ATRA Stock Holding History

Ghost Tree Capital’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-14,000	Closed	-$4.9M	–	65
2017 Q2	$4.9M	Buy	+14,000	New	+$5.39M	1.02%	39
2015 Q4	–	Sell	-4,000	Closed	-$3.14M	–	51
2015 Q3	$3.14M	Hold	4,000	–	–	1.42%	27
2015 Q2	$5.28M	Buy	+4,000	New	+$4.59M	1.71%	22

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ghost Tree Capital's ATRA Position: Q3 2017 in Review

Ghost Tree Capital sold out of Atara Biotherapeutics (ATRA) in Q3 2017, closing a stake of 14,000 shares — an estimated $4.9M sold.

Ghost Tree Capital first reported a position in ATRA in Q2 2015 and held it in 3 quarters. The position peaked at $5.28M in Q2 2015. 82 funds tracked by Wall St. Rank hold ATRA as of Q3 2017.

Ghost Tree Capital reported no remaining Atara Biotherapeutics position as of Q3 2017 after selling out during the quarter.
Ghost Tree Capital sold 14,000 Atara Biotherapeutics shares in Q3 2017, an estimated $4.9M.
Ghost Tree Capital first reported a position in Atara Biotherapeutics in Q2 2015 and held it in 3 quarters.
Ghost Tree Capital's Atara Biotherapeutics position peaked at $5.28M in Q2 2015.
82 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2017.

Based on Ghost Tree Capital's 13F filing for Q3 2017, filed 14 Nov 2017.